|Articles|October 1, 2012
Contemporary Pediatrics, Digital Edition, October 2012
New designer drugs : Legal, available, deadly
Etiologies of infectious mononucleosis
Unique sleep needs of teenagers
Puzzler : Abnormal, fidgety movements in young girl
Dermcase : New virus causes fever, rash
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
The US lost measles elimination status after 26 years; CDC and partners plan to regain it via MMR vaccination and $100M in health department funding.
At ACAAI 2026, 93.6% of pediatric biologic prescriptions needed prior authorization, 39.3% were denied, and approval took a mean of 33 days.
US preterm birth rate held at 10.4%, earning a fifth straight D+ from March of Dimes; maternal deaths fell, but racial disparities persist.
In SURMOUNT-ADOLESCENTS, tirzepatide cut BMI 18.5% at 72 weeks vs a 0.5% rise with placebo in adolescents with obesity.
Data presented at NSGC 2026 tie maternal autoantibody combinations to a non-genetic autism subtype with high recurrence risk in later-born siblings.
Caregivers reported itch, symptom, and QOL gains with roflumilast cream 0.05% in infants with AD; an FDA decision is due February 2027.
Novo Nordisk filed etavopivat for SCD in patients aged 12+, backed by phase 3 HIBISCUS data showing a 27% drop in vaso-occlusive crises vs placebo.